---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-25-000011"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:15:17.562224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track

## Summary
- Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).
- Cash, cash equivalents and short-term investments $131.9M at Dec 31, 2024.
- CMO Dr. Scott Harris will retire effective Feb 28, 2026; company to search for successor.
- Top-line data from Phase 2b IMPACT MASH trial expected Q2 2025; IND cleared for two additional indications with Phase 2 trials mid-2025.
- Board adds Teri Lawver (ex-Dexcom, J&J) and Jerry Durso (ex-Intercept CEO, Sanofi).

## SEC filing metadata
- accession: 0001326190-25-000011
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/0001326190-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/alt-20250224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-25-000011
- JSON: https://secwatch.observer/filing/0001326190-25-000011.json
- Plain text: https://secwatch.observer/filing/0001326190-25-000011.txt

## Key facts
- Executive change
  Scott Harris departed as Chief Medical Officer at Altimmune, Inc..
  - Action: retire
  - Role: Chief Medical Officer
  source text: On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/0001326190-25-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.